(XERS) – Corporate News
-
Xeris Pharmaceuticals Inc. (XERS) Enters Into an Exclusive Worldwide License Agreement for Xeriject Formulation of Teprotumumab
-
Xeris Pharmaceuticals (XERS) Updates 2023 Outlook
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to XERS Stock Lookup